Alligator Bioscience sells royalty rights to Orion for two antibodies in a €3.5 million deal.
Alligator Bioscience and Orion Corporation have amended their agreement, converting a royalty-bearing license to a fully paid, royalty-free license for two preclinical bispecific antibodies. Orion will continue developing the antibodies without paying future milestones or royalties, making a one-time payment of €3.5 million to Alligator. This deal allows Alligator to focus on advancing its lead candidate, mitazalimab, towards Phase 3 development.
November 19, 2024
5 Articles